摘要
目的:探讨肝细胞生长因子(HGF)表达与非小细胞肺癌靶向治疗耐药的相关性。方法:选取2017年6月—2021年6月我院收治的128例应用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)进行靶向治疗的非小细胞肺癌患者作为研究对象,根据是否产生EGFR-TKIs耐药,将产生耐药性的患者设为观察组,未产生耐药性的患者设为对照组,采用单因素和多因素Logistic回归分析非小细胞肺癌患者发生靶向治疗耐药的因素。结果:128例非小细胞肺癌患者中有56例发生耐药性。两组性别、年龄、肿瘤部位、肿瘤分化程度、肿瘤大小、以往化疗类型比较,差异无统计学意义(P>0.05);两组淋巴结节转移、HGF、c-MET阳性比较,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示,HGF阳性、c-MET阳性为非小细胞肺癌患者靶向治疗耐药的独立危险因素(P<0.05)。Spearman相关分析显示,HGF、c-MET表达与非小细胞肺癌靶向治疗耐药呈正相关(r=0.586、0.374,P=0.013、0.009)。结论:HGF、c-MET表达与非小细胞肺癌靶向治疗耐药密切相关,且HGF阳性、c-MET阳性为非小细胞肺癌靶向治疗耐药的独立危险因素,两者有希望成为监测和预判非小细胞肺癌分子靶向治疗耐药性的生物标记物。
Objective:To investigate the relationship between the expression of hepatocyte growth factor(HGF)and drug resistance of targeted therapy in non-small cell lung cancer.Methods:A total of 128 patients with non-small cell lung cancer who were treated with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)for targeted therapy in our hospital from June 2017 to June 2021 were selected as the research objects.According to whether EGFR-TKIs resistance was produced,the patients with drug resistance were set as the observation group,and the patients without drug resistance were set as the control group.Univariate and multivariate Logistic regression analysis was used to analyze the factors of targeted therapy resistance in patients with non-small cell lung cancer.Results:Drug resistance occurred in 56 of 128 patients with non-small cell lung cancer.There was no significant difference in gender,age,tumor location,tumor differentiation,tumor size and previous chemotherapy types between the two groups(P>0.05).There were significant differences in lymph node metastasis,HGF and c-MET positive between the two groups(P<0.05).Multivariate Logistic regression analysis showed that HGF positive and c-MET positive were independent risk factors for targeted therapy resistance in patients with non-small cell lung cancer(P<0.05).Spearman correlation analysis showed that HGF and c-MET expression were positively correlated with non-small cell lung cancer targeted therapy resistance(r=0.586,0.374,P=0.013,0.009).Conclusion:The expression of HGF and c-MET is closely related to the drug resistance of non-small cell lung cancer targeted therapy,and HGF positive and c-MET positive are independent risk factors for drug resistance of non-small cell lung cancer targeted therapy.They are expected to become biomarkers for monitoring and predicting drug resistance of non-small cell lung cancer molecular targeted therapy.
作者
王晓慧
毋乃朴
臧丹
薛云
陈亦扬
狄文玉
WANG Xiaohui;WU Naipu;ZANG Dan;XUE Yun;CHEN Yiyang;DI Wenyu(Department of Pathology,the First Affiliated Hospital of Xinxiang Medical College,Xinxiang 453000,Henan,China;Department of General Surgery,Sanquan College of Xinxiang Medical University,Xinxiang 453003,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2023年第11期1936-1939,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
肝细胞生长因子
肝细胞生长因子受体
非小细胞肺癌
靶向治疗
耐药
Hepatocyte growth factor
Hepatocyte growth factor receptor
Non-small cell lung cancer
Targeted therapy
Drug resistance
